Produtos
A Recordati Rare Diseases tem um portfólio robusto de terapias que visam uma ampla gama de condições clínicas e são projetadas para atender às necessidades de populações de pacientes carentes.
A disponibilidade e o status regulatório de nossos produtos podem variar dependendo do país. Entre em contato conosco para obter mais informações.
Brasil: https://consultas.anvisa.gov.br/#/bulario/
Consulte abaixo a versão mais atualizada dos nossos produtos, disponibilizadas no site da Agência Nacional de Vigilância Sanitária (ANVISA). Os medicamentos devem ser utilizados sob prescrição médica.
As informações sobre nossos produtos não devem ser usadas para incentivar a automedicação. Consulte sempre seu médico.
Carbaglu® (ácido carglúmico)
• bula para paciente / bula para profissional de saúde
Cystadane® (betaína anidra)
• bula para paciente / bula para profissional de saúde
Panhematin® (hemina humana)
• bula para paciente / bula para profissional de saúde
Qarziba® (dinutuximabe beta)
• bula para paciente / bula para profissional de saúde
Signifor® LP (pamoato de pasireotida)
• bula para paciente / bula para profissional de saúde
Sylvant ® (siltuximabe)
• bula para paciente / bula para profissional de saúde
Upelior® (diaspartato de pasireotida)
• bula para paciente / bula para profissional de saúde
Adverse event reporting information can be found at the bottom of this page
| Product | Generic | Indication(s) | Form | Link to SmPC (GB) | Link to PIL (GB) | Link to SmPC (NI) | Link to PIL (NI) |
|---|---|---|---|---|---|---|---|
| Carbaglu | carglumic acid | Hyperammonaemia due to N-acetylglutamate synthase primary deficiency, isovaleric acidaemia, methymalonic acidaemia or propionic acidaemia. |
200 mg tablets | Click here | Click here | Click here | Not available |
| Cosmegen Lyovac | dactinomycin | Treatment of: • Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma, and metastatic nonseminomatous testicular cancer • Gestational trophoblastic neoplasia • Locally recurrent or locoregionally metastatic melanoma |
500 µg powder | Click here | Click here | Not available | Not available |
| Cystadane | betaine anhydrous | Adjunctive treatment of homocystinuria, involving deficiencies or defects in: • Cystathionine beta-synthase • 5,10-methylene-tetrahydrofolate reductase • Cobalamin cofactor metabolism |
1 g powder | Click here | Click here | Click here | Not available |
| Cystadrops | mercaptamine hydrochloride | Treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis | 3.8 mg/ml solution | Click here | Click here | Click here | Not available |
| Cystagon | mercaptamine bitartrate | Treatment of proven nephropathic cystinosis | 50 mg capsules | Click here | Click here | Click here | Not available |
| 150 mg capsules | Click here | Click here | Click here | Not available | |||
| Isturisa▼ | osilodrostat phosphate | Treatment of endogenous Cushing's syndrome in adults | 1 mg capsules | Click here | Click here | Click here | Not available |
| 5 mg capsules | Click here | Click here | Click here | Not availble | |||
| 10 mg capsules | Click here | Click here | Click here | Not available | |||
| Ledaga | chlormethine hydrochloride | Topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma in adult patients | 160 µg/g gel | Click here | Click here | Click here | Click here |
| Normosang | human hemin | Treatment of acute attacks of hepatic porphyria | 25 mg/ml solution | Click here | Click here | Not available | Not available |
| Pedea | ibuprofen | Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age | 5 mg/ml solution | Click here | Click here | Click here | Not available |
| Signifor solution | pasireotide diaspartate | Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed | 0.3 mg solution | Click here | Click here | Click here | Not available |
| 0.6 mg solution | Click here | Click here | Click here | Not available | |||
| 0.9 mg solution | Click here | Click here | Click here | Not available | |||
| Signifor powder | pasireotide pamoate | Treatment of adult patients with: Acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue Cushing's disease for whom surgery is not an option or for whom surgery has failed. |
10 mg powder | Click here | Click here | Click here | Not available |
| 20 mg powder | Click here | Click here | Click here | Not available | |||
| 30 mg powder | Click here | Click here | Click here | Not available | |||
| 40 mg powder | Click here | Click here | Click here | Not available | |||
| 60 mg powder | Click here | Click here | Click here | Not available | |||
| Vedrop▼ | tocofersolan | Indicated in vitamin E deficiency due to digestive malabsorption in paediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis, from birth (full term newborns) up to 18 years of age | 50 mg/ml solution | Click here | Click here | Click here | Not available |
| Wilzin | zinc acetate dihydrate | Treatment of Wilson's diseases | 25 mg capsules | Click here | Click here | Click here | Not available |
| 50 mg capsules | Click here | Click here | Click here | Not available | |||
Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at (UK) https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. (Ireland) Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance www.hpra.ie. Adverse events should also be reported to Recordati Rare Diseases at Tel: +44 (0) 1491 414 333 or RRDpharmacovigilance@recordati.com.